Review: Therapeutic perspectives in bronchial vascular remodeling in COPD

Therapeutic Advances in Respiratory Disease

Volumn 2, Issue 3, 2008, Pages 179-187

  Zanini, Andrea ^a   Chetta, Alfredo ^b   Olivieri, Dario ^b  

^a IRCCS   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

airway remodeling; angiogenesis; COPD; corticosteroids

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; 6 CHLORO 7 METHOXY 8 (2 METHYLNICOTINAMIDO) BETA CARBOLINE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; AE 941; ANGIOGENESIS INHIBITOR; AZ 11557272; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BEVACIZUMAB; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 14; ML 120 B; SORAFENIB; SR 2 F; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; ASTHMA; BONE MARROW TOXICITY; BRONCHODILATING ACTIVITY; CELL FUNCTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; EMPHYSEMA; ENDOTHELIUM CELL; FATIGUE; HUMAN; HYPERTENSION; INFLAMMATION; LEUKOPENIA; LUNG ALVEOLUS CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MICROVASCULARIZATION; MUSCULOSKELETAL PAIN; NEUTROPENIA; PATHOPHYSIOLOGY; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; REVIEW; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; BRONCHI; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 68749102528     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465808092339     Document Type: Review

References (58)

1. Adcock, I.M., Chung, K.F., Caramori, G. and Ito, K. (2006) Kinase inhibitors and airway inflammation. Eur J Pharmacol 533: 118-132.
2. Barnes, P.J. (2006) Transcription factors in airway diseases. Lab Invest 86: 867-872.
3. Barnes, P.J. and Hansel, T.T. (2004) Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364: 985-996.
4. Bosken, C.H., Wiggs, B.R., Paré, P.D., Hogg, J.C. (1990) Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 142: 563-570.
5. Calabrese, C., Bocchino, V., Vatrella, A., Marzo, C., Guarino, C., Mascitti, S. et al. (2006) Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Resp Med 100: 1415-1422.
6. Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A. et al. (2003) TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361: 449-456.
7. Carmeliet, P. (2003) Angiogenesis in health and disease. Nat Med 9: 653-660.
8. Celedòn, J.C., Lange, C., Raby, B.A., Litonjua, A.A., Palmer, L.J., DeMeo, D.L. et al. (2004) The transforming growth factor-beta1 gene is associated with chronic obstructive pulmonary disease. Hum Mol Genet 13: 1649-1656.
9. Chetta, A., Zanini, A., Torre, O. and Olivieri, D. (2007) Vascular remodelling and angiogenesis in asthma: morphological aspects and pharmacological modulation. Inflamm Allergy Drug Targets 1: 41-45.
10. Chetta, A., Zanini, A., Foresi, A., Del Donno, M., Castagnaro, A., D'Ippolito, R. et al. (2003) Vascular component of airway remodelling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 167: 751-757.
11. Churg, A., Wang, R., Wang, X., Onnervik, P.O., Thim, K. and Wright, J.L. (2007) Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 62: 706-713.
12. Cohen, M.H., Gootenberg, J., Keegan, P., Pazdur, R. (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718.
13. Daheshia, M. (2005) Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic pulmonary disease (COPD). Curr Med Res Opin 21: 587-594.
14. de Boer, W.I., Alagappan, V.K.T. and Sharma, H.S. (2007) Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy. Cell Biochem Biophys 47: 131-148.
15. de Boer, W.I., van Schadewijk, A., Sont, J.K., Sharma, H.S., Stolk, J., Hiemstra, P.S. and van Krieken, J.H. (1998) Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158: 1951-1957.
16. Folkman, J. (1995) Clinical applications of research on angiogenesis. New Engl J Med 333: 1757-1763.
17. Gerber, H.P., Dixit, V. and Ferrara, N. (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273: 13313-13316.
18. Gingras, D., Boivin, D., Deckers, C., Gendron, S., Barthomeuf, C. and Béliveau, R. (2003) Neovastat-a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14: 91-96.
19. Greiff, L., Andersson, M., Erjefålt, J.S., Persson, C.G. and Wollmer, P. (2003) Airway microvascular extravasation and luminal entry of plasma. Clin Physiol Funct Imaging 23: 301-306.
20. Gridelli, C., Maione, P., Del Gaizo, F., Colantuoni, G., Guerriero, C., Ferrara, C. et al. (2007) Sorafenib and Sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 12: 191-200.
21. Hashimoto, M., Tanaka, H. and Abe, S. (2005) Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD. Chest 127: 965-972.
22. Hogg, J.C., Chu, F., Utokaparch, S., Woods, R., Elliott, W.M., Buzatu, L. et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645-2653.
23. Horvath, G. and Wanner, A. (2006) Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J 27: 172-187.
24. Hoshino, M., Takahashi, M., Takai, Y., Sim, J. and Aoike, N. (2001) Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy 31: 722-730.
25. Jerkic, M., Rivas-Elena, J.V., Prieto, M., Carròn, R., Sanz-Rodriguez, F., Pérez-Barriocanal, F. et al. (2004) Endoglin regulates nitric oxide-dependent vasodilatation. Faseb J 18: 609-611.
26. Kanazawa, H. (2007) Role of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Med Sci Monit 13: RA189-195.
27. Kanazawa, H., Asai, K., Hirata, K. and Yoshikawa, J. (2003) Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 114: 354-358.
28. Kranenburg, A.R., Willems-Widyastuti, A., Mooi, W.J., Sterk, P.J., Alagappan, V.K.T., de Boer, W.I. et al. (2006) Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Clin Pathol 126: 725-735.
29. Kranenburg, A.R., de Boer, W.I., Alagappan, V.K.T., Sterk, P.J. and Sharma, H.S. (2005) Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax 60: 106-113.
30. Kranenburg, A.R., Willems-Widyastuti, A., Mooi, W.J., Saxena, P.R., Sterk, P.J., de Boer, W.I. and Sharma, H.S. (2005) Chronic obstructive pulmonary disease is associated with enhanced expression of FGF-1, FGF-2 and FGFR-1. J Pathol 206: 28-38.
31. Kuwano, K., Bosken, C.H., Paré, P.D., Bai, T.R., Wiggs, B.R. and Hogg, J.C. (1993) Small airways dimensions in asthma and chronic obstructive pulmonary disease. Am Rev Respir Dis 148: 1220-1225.
32. Laird, A.D., Christensen, J.G., Li, G., Carver, J., Smith, K., Xin, X. et al. (2002) SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16: 681-690.
33. Lebrin, F., Goumans, M.J., Jonker, L., Carvalho, R.L.C., Valdimarsdottir, G., Thorikay, M. et al. (2004) Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. Embo J 23: 4018-4028.
34. Lee, S.Y. and Chung, S.M. (2007) Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2alpha suppression. Vascul Pharmacol 47: 313-318.
35. Mahabeleshwar, G.H., Feng, W., Reddy, K., Plow, E.F. and Byzova, T.V. (2007) Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 101: 570-580.
36. Mendes, E.S., Campos, M.A., Hurtado, A. and Wanner, A. (2004) Effect of montelukast and fluticasone propionate on airway mucosal blood flow in asthma. Am J Respir Crit Care Med 169: 1131-1134.
37. Newton, R., Holden, N.S., Catley, M.C., Oyelusi, W., Leigh, R., Proud, D. et al. (2007) Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors. J Pharmacol Exp Ther 321: 734-742.
38. Orsida, B.E., Ward, C., Li, X., Bish, R., Wilson, J.W., Thien, F. et al. (2001) Effect of a long-acting β2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 164: 117-121.
39. Orsida, B.E., Li, X., Hickey, B., Thien, F., Wilson, J.W. and Walters, E.H. (1999) Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 54: 289-295.
40. Pauwels, R.A., Buist, A.S., Calverley, P.M., Jenkins, C.R. and Hurd, S.S. (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 163: 1256-1276.
41. Renda, T., Baraldo, S., Pelaia, G., Bazzan, E., Turato, G., Papi, A. et al. (2008) Increased activation of p38 MAPK in COPD. Eur Respir J 31: 62-69.
42. Riely, G.J. and Miller, V.A. (2007) Vascular endothelial growth factor trap in non-small cell lung cancer. Clin Cancer Res 13: 4623s-4627s.
43. Risau, W. and Flamme, I. (1995) Vasculogenesis. A Rev Cell Dev Biol 11: 73-91.
44. Saetta, M., Turato, G., Maestrelli, P., Mapp, C.E. and Fabbri, L.M. (2001) Cellular and structural changes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163: 1304-1309.
45. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 55: 2542-2550.
46. Sessa, C., Viganò, L., Grasselli, G., Trigo, J., Marimon, I., Lladò, A. et al. (2006) Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 42: 171-178.
47. Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G. and Bussolino, F. (1999) Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18: 882-892.
48. Sutherland, E.R. and Cherniack, R.M. (2004) Management of chronic obstructive pulmonary disease. N Engl J Med 350: 2689-2697.
49. Takizawa, H., Tanaka, M., Takami, K., Ohtoshi, T., Ito, K., Satoh, M. et al. (2001) Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163: 1476-1483.
50. Tanaka, H., Yamada, G., Saikai, T., Hashimoto, M., Tanaka, S., Suzuki, K. et al. (2003) Increased airway vascularity in newly diagnosed asthma using a high-magnification bronchovideoscope. Am J Respir Crit Care Med 168: 1495-1499.
51. van Hinsbergh,V.W. and Koolwijk, P. (2008) Endothelial sprouting and angiogenesis: metalloproteinases in the lead. Cardiovasc Res (Epub ahead of print).
52. Vernooy, J.H., Lindeman, J.H., Jacobs, J.A., Hanemaaijer, R. and Wouters, E.F. et al. (2004) Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 126: 1802-1810.
53. Vignola, A.M., Paganin, F., Capieu, L., Scichilone, N., Bellia, M., Maakel, L. et al. (2004) Airway remodelling assessed by sputum
54. and high-resolution computed tomography in asthma and COPD. Eur Respir J 24: 910-917.
55. Widdicombe, J. (1993) New perspectives on basic mechanisms in lung disease. Why are the airways so vascular? Thorax 48: 290-295.
56. Wilson, J.W. and Kotsimbos, T. (2003) Airway vascular remodeling in asthma. Curr Allergy Asthma Rep 3: 153-158.
57. Yang,Y.A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J.J., MacGregor, J. et al. (2002) Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109: 1607-1615.
58. Zanini, A., Chetta, A., Nicolini, G., Castagnetti, C., D’ Ippolito, R., Neri, M. et al. (2007) Vascular remodeling and inhaled beclomethasone dipropionate in copd. ERS Annual Congress 598s.